Unlock stock picks and a broker-level newsfeed that powers Wall Street.

HKSE - Delayed Quote HKD

Brii Biosciences Limited (2137.HK)

Compare
1.780
+0.020
+(1.14%)
At close: April 17 at 4:08:07 PM GMT+8

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Dr. Zhi Hong Ph.D. Co-founder, Executive Chairman of the Board & CEO 10.32M -- 1964
Dr. Ankang Li C.F.A., J.D., Ph.D. Chief Financial & Strategy Officer, Company Secretary and Executive Director 6.33M -- 1979
Dr. Eleanor de Groot Ph.D. Chief Technology Officer -- -- 1969
Dr. Brian Alvin Johns Ph.D. Chief Scientific Officer -- -- --
Sarah Qiu Associate Director of Investor Relations -- -- --
Ms. Karen Del Barrio Neuendorff Chief People Officer & Head of Human Resources -- -- 1976
Mr. Coy Stout Head of Patient Advocacy -- -- 1972
Dr. Lianhong Xu Ph.D. Head of Discovery -- -- 1967
Dr. Qing Zhu Ph.D. Head of China Research & Development -- -- 1968
Dr. David Margolis M.D., M.P.H. Chief Medical Officer -- -- 1975

Brii Biosciences Limited

Building 7, International Science Park
3rd Floor, Zhongguancun Dongsheng No. 1 North Yongtaizhuang Road Haidian District
Beijing, 100192
China
https://www.briibio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
98

Description

Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.

Corporate Governance

Brii Biosciences Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 21, 2025 at 10:59 AM UTC

Brii Biosciences Limited Earnings Date

Recent Events

Related Tickers

2171.HK CARsgen Therapeutics Holdings Limited
12.740
+3.24%
 
2315.HK Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
11.800
+3.87%
 
2162.HK Keymed Biosciences Inc.
42.650
+2.40%
 
1167.HK JACOBIO-B
3.140
+1.29%
 
9939.HK Kintor Pharmaceutical Limited
1.100
-0.90%
 
2142.HK HBM Holdings Limited
7.180
0.00%
 
6628.HK Transcenta Holding Limited
1.150
0.00%
 
6660.HK AIM Vaccine Co., Ltd.
3.200
-0.31%
 
2511.HK HighTide Therapeutics, Inc.
1.650
+3.77%
 
9966.HK Alphamab Oncology
6.630
+1.07%